Prosthetic

ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million

YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery…

1 year ago

ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens

YONKERS, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery…

1 year ago

ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee

YONKERS, N.Y., April 26, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery…

2 years ago

ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee

YONKERS, New York, April 03, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the…

2 years ago

ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Update

YONKERS, N.Y., March 31, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery…

2 years ago

Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMD

Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMD Pixium Vision to receive interactive communication…

2 years ago

Quipt Home Medical Reports Record First Quarter Fiscal 2023 Financial Results Posting Positive Net Income, Revenue Growth of 38% and Adjusted EBITDA Growth of 50%

Posts Strong Adjusted EBITDA Margin of 22% and Sequential Organic Growth of 2%CINCINNATI, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Quipt…

2 years ago

ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Continued execution to advance exebacase and CF-370 into new clinical studiesYONKERS, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation…

2 years ago

Osteal Therapeutics, Inc. Completes Enrollment in APEX Phase 2 Clinical Trial of VT-X7 for Periprosthetic Joint Infection

Six-month outcomes are expected in second quarter of 2023DALLAS, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a…

2 years ago

Eurospine Congress a very successful meeting with spine professionals for Spineway

Press Release         Ecully, 28th of October, 2022 – 8:45 am Remarkable participation at 2022 Eurospine congress in Milan Spineway and…

2 years ago
Show more Posts
Show previous Posts